Insulin resistance used to sit in an uncomfortable space in medicine. There wasn’t a quick fix for it, just diet and exercise advice that most people heard and mostly ignored. That has changed. GLP-1 prescribing has grown sharply over the past decade, and clinical guidance has shifted toward earlier pharmaceutical intervention for prediabetes and metabolic syndrome rather than lifestyle change first. This is a legitimate option in many cases. It has also quietly demoted exercise from the primary lever to something to combine with medication, even in some clinical guidelines.
The research on exercise and insulin sensitivity tells a different story about where the lever actually is. This article looks at what insulin resistance is, why skeletal muscle is the tissue most directly responsible for it, what the exercise research actually shows, and how medication and exercise fit together rather than compete.
What Insulin Resistance Actually Is
Insulin resistance describes a state in which cells, primarily in skeletal muscle, the liver, and fat tissue, respond less effectively to insulin’s signal to take up glucose from the bloodstream. The pancreas compensates by producing more insulin to achieve the same glucose-clearing effect. Over time, this compensation can fail, and blood glucose rises, which is the trajectory toward type 2 diabetes.
Skeletal muscle is the largest single contributor to this picture. It accounts for roughly 80% of insulin-stimulated glucose disposal in the body. This is not a minor detail. It means the tissue most responsible for clearing glucose after a meal is also the tissue most directly trainable through exercise, independent of whatever is happening with diet, weight, or medication.
The Shift Toward Medication First
GLP-1 receptor agonist prescribing has expanded considerably. In one analysis of new type 2 diabetes patients, GLP-1 use rose from under 2.5% to 21% of patients within a decade. Clinical guidance for 2026 explicitly frames early pharmacological intervention for prediabetes and metabolic syndrome as a way to prevent progression to type 2 diabetes, often alongside lifestyle changes rather than after them.
This is not a criticism of the medication. GLP-1 receptor agonists and metformin both improve insulin sensitivity through legitimate, well-studied mechanisms, and for many people they are effective and appropriate. The point worth making plainly is that this shift has changed the cultural framing of insulin resistance from a problem you train your way out of to a problem you medicate your way out of, with exercise relegated to a supporting role in most public-facing guidance.
What the Exercise Research Shows
The exercise research on insulin resistance has continued to develop, and recent reviews are specific about modality, not just “more activity.”
A 2025 narrative review on glucose metabolism in older adults found that combined training, aerobic plus resistance, produced more comprehensive improvements across multiple metabolic markers than either modality alone over the long term. A separate systematic review covering 26 studies on type 2 diabetes identified five exercise protocols that improved insulin function or glycemic control, spanning aerobic, resistance, interval, and combined formats. A mesh meta-analysis across nine exercise interventions in diabetic patients found that cycling, resistance training, and combined aerobic-resistance training all improved fasting glucose, insulin secretion, and insulin sensitivity.
The mechanistic detail that matters most for this discussion is that resistance training improves muscle glucose uptake through pathways that do not require significant weight loss. Increased GLUT4 (protein in your muscle and fat cells that actually does the job of pulling glucose in from the bloodstream) transporter density and improved muscle glucose disposal capacity occur as a direct training adaptation. This is the part that tends to get lost when insulin resistance is framed mainly as a weight problem. The muscle adapts and starts handling glucose more effectively because it was trained to, not only because the person lost weight.
Why This Matters Beyond the Mechanism
None of this makes the case that exercise should replace medication, or that medication is the wrong choice. The honest position is that exercise and medication are not competing solutions. They improve insulin sensitivity through different pathways, GLP-1 agonists primarily through enhanced insulin secretion and appetite-driven weight loss, exercise primarily through direct adaptation in the tissue responsible for most glucose disposal, and many people will reasonably use both.
What is worth correcting is the undersold position exercise has been given in the broader conversation. Skeletal muscle is mechanically built to address insulin resistance directly. Training it is not a secondary lifestyle recommendation sitting alongside the real treatment. It is targeting the same problem through the tissue most responsible for it.
Why Generic Exercise Advice Falls Short
The standard advice given for insulin resistance, move more, walk daily, get some activity, is not wrong, but it understates what the research supports. Combined training, structured resistance work paired with aerobic activity, produces the most comprehensive improvement across markers. Generic walking-based advice, while better than nothing, does not engage the resistance training pathways that drive the GLUT4 and muscle glucose uptake adaptations described above.
This is where dose and modality become relevant in a way that generic guidance does not address. A training stimulus that is too light produces minimal adaptation. A training stimulus that exceeds what someone can currently recover from produces accumulated fatigue rather than improvement, particularly relevant for people who are deconditioned or managing other health factors alongside insulin resistance. Getting this right is not a matter of doing more exercise. It is a matter of applying the right exercise, monitored and adjusted as the person’s capacity changes.
This is the same principle that runs through training response monitoring generally. Knowing that a session happened is not the same as knowing what it cost the person physiologically, or whether the stimulus was appropriate for where they currently are. For someone using exercise as part of managing insulin resistance, tracking how training is actually landing, not just whether it occurred, is what separates a programme that meaningfully shifts insulin sensitivity from one that is simply movement.
References
- Zhang Q, Guo Y, Zhang H, Xu W, Yin L. Effects of aerobic, resistance, interval, and combined training on glucose metabolism in older adults: insights into type, dose, and mechanism. Front Physiol. 2025;16:1702669. DOI: 10.3389/fphys.2025.1702669
- Effects of nine different exercise interventions on insulin sensitivity in diabetic patients: a systematic review and network meta-analysis. Front Endocrinol. 2025. DOI: 10.3389/fendo.2025.1409474
- Optimizing exercise for type 2 diabetes management: comparative insights from aerobic, resistance, interval and combined training protocols. Metabolites. 2025;15:739. PMC: PMC12654782
- Rashwan B, et al. Differential effects of aerobic, resistance, and combined trainings on first- and second-phase insulin secretion and glucose effectiveness in type 2 diabetes: a randomized controlled trial. J Diabetes Res. 2025;2025:9922344. DOI: 10.1155/jdr/9922344
- Trends in pharmacological treatment of patients with new onset type 2 diabetes: usage patterns in an evolving guideline landscape. 2024. PMC: PMC12134773
Leave a Reply
You must be logged in to post a comment.